Pretreatment with myo-inositol in non polycystic ovary syndrome patients undergoing multiple follicular stimulation for IVF: a pilot study

Reproductive Biology and Endocrinology

Research

Franco Lisi¹  Piero Carfagna¹  Mario Montanino Oliva¹  Rocco Rago¹  Roberta Poverini¹  Rosella Lisi¹  Roberto Marci²  Valeria Raparelli³  Elena Vaquero⁴  Donatella Caserta⁵  Massimo Moscarini⁵  Claudio Manna⁶ 

[1] Center for Reproductive Medicine Research, Clinica Villa Mafalda, Rome, Italy;Department of Biomedical Sciences and Advanced Therapies, Section of Obstetrics and Gynecology, University Hospital of Ferrara, Ferrara, Italy;Department of Internal Medicine and Medical Specialties, Sapienza - University of Rome, Rome, Italy;Department of Surgery, Tor Vergata - University of Rome, Rome, Italy;Department of Women Health and Territorial Medicine, Sapienza - University of Rome, Sant’Andrea Hospital, Rome, Italy;GENESIS Center for Reproductive Medicine, Rome, Italy;

关键词: Myo-inositol;    Inositol;    Follicle;    Stimulation;    IVF;    ICSI;    Oocytes;    Embryos;   

DOI  :  10.1186/1477-7827-10-52

 received in 2012-04-14, accepted in 2012-07-09,  发布年份 2012

来源: Springer

【 摘 要 】

BackgroundAim of this pilot study is to examine the effects of myo-inositol administration on ovarian response and oocytes and embryos quality in non PolyCystic Ovary Syndrome (PCOS) patients undergoing multiple follicular stimulation and in vitro insemination by conventional in vitro fertilization or by intracytoplasmic sperm injection.MethodsOne hundred non-PCOS women aged <40 years and with basal FSH <10 mUI/ml were down-regulated with triptorelin acetate from the mid-luteal phase for 2 weeks, before starting the stimulation protocol for oocytes recovery. All patients received rFSH, at a starting dose of 150 IU for 6 days. The dose was subsequently adjusted according to individual response. Group B (n = 50) received myo-inositol and folic acid for 3 months before the stimulation period and then during the stimulation itself. Group A (n-50) received only folic acid as additional treatment in the 3 months before and through treatment.ResultsTotal length of the stimulation was similar between the two groups. Nevertheless, total amount of gonadotropins used to reach follicular maturation was found significantly lower in group B. In addition, the number of oocytes retrieved was significantly reduced in the group pretreated with myo-inositol. Clinical pregnancy and implantation rate were not significantly different in the two groups.ConclusionsOur findings suggest that the addition of myo-inositol to folic acid in non PCOS-patients undergoing multiple follicular stimulation for in-vitro fertilization may reduce the numbers of mature oocytes and the dosage of rFSH whilst maintaining clinical pregnancy rate. Further, a trend in favor of increased incidence of implantation in the group pretreated with myo-inositol was apparent in this study. Further investigations are warranted to clarify this pharmacological approach, and the benefit it may hold for patients.

【 授权许可】

CC BY   
© Lisi et al.; licensee BioMed Central Ltd. 2012